Aligos Therapeutics/$ALGS
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Aligos Therapeutics
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.
- Ticker
- $ALGS
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 82
- Headquarters
- South San Francisco, United States
- Website
- www.aligos.com
ALGS Metrics
BasicAdvanced
$35M
-
-$7.31
2.33
-
Price and volume
Market cap
$35M
Beta
2.33
52-week high
$13.69
52-week low
$3.98
Average daily volume
51K
Financial strength
Current ratio
2.192
Quick ratio
2.052
Long term debt to equity
0.009
Total debt to equity
0.11
Profitability
EBITDA (TTM)
-77.916
Gross margin (TTM)
-180.40%
Net profit margin (TTM)
-241.01%
Operating margin (TTM)
-250.63%
Effective tax rate (TTM)
-4.42%
Revenue per employee (TTM)
$380,000
Management effectiveness
Return on assets (TTM)
-49.12%
Return on equity (TTM)
-113.59%
Valuation
Price to revenue (TTM)
1.828
Price to book
1.08
Price to tangible book (TTM)
1.08
Price to free cash flow (TTM)
-0.61
Free cash flow yield (TTM)
-164.04%
Free cash flow per share (TTM)
-9.088
Growth
Revenue change (TTM)
893.01%
Earnings per share change (TTM)
-22.79%
3-year revenue growth (CAGR)
22.25%
3-year earnings per share growth (CAGR)
-46.56%
ALGS Financial Performance
Revenues and expenses
ALGS Earnings Performance
Company profitability
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.